PDF belimumab.pdf | Request a copy Full text restricted Available under University of Tasmania Standard License.

Abstract

Belimumab, the lead in a series of human monoclonal antibodies against the human protein B-lymphocyte stimulator (BLyS), is under development by Human Genome Sciences, Cambridge Antibody Technology and GlaxoSmithKline for the potential treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). By January 2006, belimumab had completed phase II clinical trials in SLE and RA; a phase III clinical SLE trial is scheduled to begin later this year.

Item Type:	Article
Authors/Creators:	Ding, C and Jones, G
Journal or Publication Title:	Current Opinion in Investigational Drugs
ISSN:	1472-4472
Additional Information:	restricted - published by Thompson
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page